SCHEMBL6825524

SCHEMBL6825524

CCOC(=O)c1[nH]c(C)c(-c2ccc(C(=O)NCc3ccccc3OC)cc2)c1C

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
NPC1 O15118 1/20 0.66
HPGD P15428 3/20 0.56
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
MAPT P10636 3/20 0.55
POLB P06746 1/20 0.55
HDAC1 Q13547 1/20 0.55
P2RY12 Q9H244 1/20 0.54
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.47
ROCK2 O75116 1/20 0.46
ROCK1 Q13464 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6825305 0.89 ALDH1A1 (0.52) HTTSMN1; SMN2NPC1HPGDMAPT
SCHEMBL6825631 0.85 LMNA (0.58) HTTSMN1; SMN2NPC1KMT2AMAPT
SCHEMBL6828519 0.84 RXFP1 (0.58) HTTSMN1; SMN2NPC1HPGDMEN1
SCHEMBL6828555 0.82 SMN1; SMN2 (0.70) SMN1; SMN2NPC1MEN1KMT2APOLB
SCHEMBL6828200 0.81 ROCK2 (0.57) SMN1; SMN2HPGDPOLBROCK2ROCK1
SCHEMBL6828221 0.81 LMNA (0.57) HTTSMN1; SMN2HPGDMEN1KMT2A
SCHEMBL6828203 0.78 MAPT (0.60) HTTSMN1; SMN2NPC1HPGDMEN1
SCHEMBL6825636 0.78 EPHX2 (0.55) SMN1; SMN2NPC1MEN1KMT2AMAPT
SCHEMBL6830213 0.77 KDM4E (0.59) HTTSMN1; SMN2NPC1MEN1KMT2A
SCHEMBL6828198 0.76 MAPT (0.60) HTTSMN1; SMN2NPC1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138269-A1 Substituted pyrroles as kinase inhibitors SUGEN, INC. 2004-07-15 US claimed
US-20040138269-A1 Substituted pyrroles as kinase inhibitors SUGEN, INC. 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138269-A1 Substituted pyrroles as kinase inhibitors PHKG1, PHKG2, MAP3K20 HTT 1942/4885SMN1; SMN2 2661/4885NPC1 2915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.